OPN-6602

Phase 1Small molecule

OOpna Bio LLC

OPN-6602 is one of 25 small molecule programs targeting Multiple Myeloma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Nolvadex

AstraZeneca

Preclinical

1 7

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 8

Intron a

Systemic Therapy

1 10

Abecma

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Recruiting·OOpna Bio LLC·Phase 1·NCT06433947·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OPN-6602. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OPN-6602 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OPN-6602. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Opna Bio LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: OOpna Bio LLC

OPN-6602

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News